Interleukin (IL)-33, a member of the IL-1 family of cytokines, is involved in innate and adaptive immune responses. IL-33 triggers pleiotropic immune functions in multiple types of immune cells, which express the IL-33 receptor, ST2. Recent studies have revealed the potential applications of IL-33 for treating acute kidney injury in preclinical animal models. However, IL-33 and IL-33-responding immune cells are reported to exhibit both detrimental and beneficial roles. The IL-33-mediated immunomodulatory functions have been investigated using loss-of-function approaches, such as IL33-deficient mice, IL-33 antagonists, or administration of exogenous IL-33 recombinant protein. This review will discuss the key findings on IL-33-mediated activation of kidney resident group 2 innate lymphoid cells (ILC2s) and summarize the current understanding of the differential functions of endogenous IL-33 and exogenous IL-33 and their potential implications in treating acute kidney injury.
CITATION STYLE
Chen, W. Y., Li, L. C., Wu, Y. H., Yang, J. L., & Tzeng, H. T. (2020). Emerging roles of interleukin-33-responsive kidney group 2 innate lymphoid cells in acute kidney injury. International Journal of Molecular Sciences, 21(4). https://doi.org/10.3390/ijms21041544
Mendeley helps you to discover research relevant for your work.